Reneo Pharmaceuticals to Present Preclinical Mavodelpar Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake City, Utah, Mar. 18-21, 2023.

  Presentation  
PPARδ Agonist REN001 Improves Mitochondrial Function in Skeletal Muscle: A Potential Treatment for Primary Mitochondrial Myopathies  

  Date and Time  
Presenter : John Adams Ph.D., Senior Vice President, Translational Science
Session : Sunday, Mar. 19, 2023, from 7:00-10:00 p.m. MST

The poster highlights the findings of pharmacological and biochemical studies which demonstrate that mavodelpar (REN001) is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), resulting in increased fatty acid metabolism. Further, mavodelpar activation of PPARδ in mice was found to increase expression of genes involved in fatty acid metabolism, oxidative phosphorylation, and mitochondrial biogenesis.

Mavodelpar is currently being evaluated in a pivotal randomized controlled clinical trial, REN001-201 (STRIDE; NCT04535609) in adult patients with primary mitochondrial myopathies (PMM) with confirmed mitochondrial DNA (mtDNA) defects. The poster presentation will be available on the Presentations and Publications page of the Reneo Pharmaceuticals website following the event.

  About Reneo Pharmaceuticals  

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase production of new mitochondria. For additional information, please see reneopharma.com .

  About Mavodelpar  

Mavodelpar (REN001) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). For additional information, please see clinicaltrials.gov .

  About PMM  

PMM are a group of rare, genetic metabolic disorders caused by mutations or deletions in the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). These genetic alterations hamper the ability of mitochondria to generate energy from nutrient sources, resulting in energy deficits that are most pronounced in tissues with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness, exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.

  Forward-Looking Statements  

  Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the completion of enrollment of clinical trials, announcement of topline data from the STRIDE study, and the submission of marketing applications. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will," "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo's business in general, and the other risks described in Reneo's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.  

  Contacts:  

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com  

David Melamed, Ph.D.
Media Inquiries
Russo Partners, LLC
david.melamed@russopartnersllc.com